论文部分内容阅读
用流行性出血热病毒(EHFV)76-118株免疫猪制备特异性转移因子(STF),对流行性出血热(EHF)62例早期患者进行临床疗效观察。其中,STF组(STF+综合疗法)37例,对照组(综合疗法)25例,两组有可比性。经临床使用证明,STF配合综合疗法,对EHF早期病人有显著疗效。STF可以提高EHF患者的细胞免疫功能,在退热、促进血小板复常、减少出血倾向及预防肾脏损害等方面有较好的作用。在提高越期率、缩短治愈时间等方面的效果较对照组更为明显。
The specific transfer factor (STF) was prepared from pigs immunized with epidemic hemorrhagic fever virus (EHFV) 76-118 and the clinical efficacy of 62 cases of early epidemic hemorrhagic fever (EHF) were observed. Among them, STF group (STF + combination therapy) 37 cases, control group (25 cases), the two groups were comparable. The clinical use of proven, STF combined with comprehensive therapies, EHF early patients have a significant effect. STF can improve cellular immune function in patients with EHF, which has a good effect in the aspects of antipyretics, promotion of platelet normalization, reduction of bleeding tendency and prevention of kidney damage. In improving the overdue rate, shorten the cure time and other aspects of the effect is more obvious than the control group.